Oncomatrix Research Group, Department of Biomedicine, University of Bergen, Jonas Lies vei 91 5009 Bergen, Norway.
Oncomatrix Research Group, Department of Biomedicine, University of Bergen, Jonas Lies vei 91 5009 Bergen, Norway; Department of Neurosurgery, Haukeland University Hospital, Jonas Lies vei, 71, 5021 Bergen, Norway.
Pharmacol Res. 2017 Oct;124:74-91. doi: 10.1016/j.phrs.2017.07.013. Epub 2017 Jul 13.
Cancer is a major health issue worldwide, and the global burden of cancer is expected to increase in the coming years. Whereas the limited success with current therapies has driven huge investments into drug development, the average number of FDA approvals per year has declined since the 1990s. This unmet need for more effective anti-cancer drugs has sparked a growing interest for drug repurposing, i.e. using drugs already approved for other indications to treat cancer. As such, data both from pre-clinical experiments, clinical trials and observational studies have demonstrated anti-tumor efficacy for compounds within a wide range of drug classes other than cancer. Whereas some of them induce cancer cell death or suppress various aspects of cancer cell behavior in established tumors, others may prevent cancer development. Here, we provide an overview of promising candidates for drug repurposing in cancer, as well as studies describing the biological mechanisms underlying their anti-neoplastic effects.
癌症是全球范围内的一个主要健康问题，预计未来几年全球癌症负担将增加。虽然当前疗法的有限成功推动了对药物开发的大量投资，但自 20 世纪 90 年代以来，每年获得 FDA 批准的药物数量却有所下降。这种对更有效抗癌药物的未满足需求，引发了人们对药物再利用（即使用已批准用于其他适应症的药物来治疗癌症）的日益关注。因此，来自临床前实验、临床试验和观察性研究的数据都表明，除癌症外，广泛的药物类别中的化合物具有抗肿瘤功效。其中一些化合物可诱导癌细胞死亡或抑制已建立的肿瘤中癌细胞行为的各个方面，而另一些化合物则可能预防癌症的发生。在这里，我们概述了癌症药物再利用的有前途的候选药物，以及描述其抗肿瘤作用的生物学机制的研究。
